Sarah Young
#78,710
Most Influential Person Now
New Zealand immunologist
Sarah Young 's AcademicInfluence.com Rankings
Sarah Young biology Degrees
Biology
#3182
World Rank
#4902
Historical Rank
Immunology
#128
World Rank
#135
Historical Rank
Download Badge
Biology
Sarah Young 's Degrees
- Bachelors Immunology University of Auckland
- Masters Immunology University of New Zealand
Why Is Sarah Young Influential?
(Suggest an Edit or Addition)According to Wikipedia, Sarah Louise Young is a New Zealand immunology academic, and as of 2014 was head of pathology at the University of Otago. From 2020-2023 she ran the School of Medical Sciences at the University of Sydney. In 2023 Prof Young was appointed as the Executive Dean of the Faculty of Science at the University of Canterbury, New Zealand.
Sarah Young 's Published Works
Published Works
- Proteomic analysis of melanoma‐derived exosomes by two‐dimensional polyacrylamide gel electrophoresis and mass spectrometry (2004) (311)
- Bifidobacterial Species Differentially Affect Expression of Cell Surface Markers and Cytokines of Dendritic Cells Harvested from Cord Blood (2004) (163)
- Virus-like particle vaccines: immunology and formulation for clinical translation (2018) (96)
- Cross‐presentation of epitopes on virus‐like particles via the MHC I receptor recycling pathway (2011) (82)
- The Effects of Obesity on Anti-Cancer Immunity and Cancer Immunotherapy (2020) (52)
- Environmental Strains of Mycobacterium avium Interfere with Immune Responses Associated with Mycobacterium bovis BCG Vaccination (2007) (51)
- Manipulation of immune responses to Mycobacterium bovis by vaccination with IL‐2‐ and IL‐18‐secreting recombinant bacillus Calmette Guerin (2002) (49)
- Virus-like particles from rabbit hemorrhagic disease virus can induce an anti-tumor response. (2008) (43)
- Oncolytic virus-derived type I interferon restricts CAR T cell therapy (2020) (41)
- IL-2-secreting recombinant bacillus Calmette Guerin can overcome a Type 2 immune response and corticosteroid-induced immunosuppression to elicit a Type 1 immune response. (2002) (40)
- Mannosylation of Virus-Like Particles Enhances Internalization by Antigen Presenting Cells (2014) (39)
- Virus-like particles and α-galactosylceramide form a self-adjuvanting composite particle that elicits anti-tumor responses. (2012) (39)
- Cytokine‐modified Mycobacterium smegmatis as a novel anticancer immunotherapy (2004) (38)
- Transcutaneous vaccination with virus-like particles. (2006) (38)
- An Enhanced Heterologous Virus-Like Particle for Human Papillomavirus Type 16 Tumour Immunotherapy (2013) (34)
- Antigen delivery by virus-like particles for immunotherapeutic vaccination. (2014) (33)
- Antigen Incorporated In Virus-like Particles Is Delivered to Specific Dendritic Cell Subsets That Induce An Effective Antitumor Immune Response In Vivo (2013) (31)
- Intracellular Cleavable CpG Oligodeoxynucleotide-Antigen Conjugate Enhances Anti-tumor Immunity. (2017) (26)
- Enhancing the immunogenicity of tumour lysate-loaded dendritic cell vaccines by conjugation to virus-like particles (2011) (23)
- Virus-Like Particles, a Versatile Subunit Vaccine Platform (2014) (21)
- DNA fusion vaccines incorporating IL-23 or RANTES for use in immunization against influenza. (2008) (17)
- Adoptive cell therapy with CD4+ T helper 1 cells and CD8+ cytotoxic T cells enhances complete rejection of an established tumour, leading to generation of endogenous memory responses to non-targeted tumour epitopes (2017) (15)
- Conditions for the generation of cytotoxic CD4+ Th cells that enhance CD8+ CTL-mediated tumor regression (2016) (15)
- The Delta-Subunit Selective GABAA Receptor Modulator, DS2, Improves Stroke Recovery via an Anti-inflammatory Mechanism (2019) (14)
- Multi-target chimaeric VLP as a therapeutic vaccine in a model of colorectal cancer (2017) (13)
- Bystander Help within a Polyepitope DNA Vaccine Improves Immune Responses to Influenza Antigens (2004) (12)
- Multi-target chimaeric VLP as a therapeutic vaccine in a model of colorectal cancer (2017) (12)
- Immunogenicity and protective efficacy of mycobacterial DNA vaccines incorporating plasmid‐encoded cytokines against Mycobacterium bovis (2010) (11)
- Delivering Two Tumour Antigens Survivin and Mucin-1 on Virus-Like Particles Enhances Anti-Tumour Immune Responses (2021) (10)
- Comparative Study of 5′- and 3′-Linked CpG–Antigen Conjugates for the Induction of Cellular Immune Responses (2017) (10)
- Functionalisation of Virus-Like Particles Enhances Antitumour Immune Responses (2019) (9)
- Suppression of the CD8 T cell response by human papillomavirus type 16 E7 occurs in Langerhans cell-depleted mice (2016) (7)
- Potent Antietumor Immunity in Mice Induced by Vaccination With an Ovine Atadenovirus Vector (2012) (7)
- Molecular monitoring of glioblastoma's immunogenicity using a combination of Raman spectroscopy and chemometrics. (2021) (7)
- Combining dendritic cells and B cells for presentation of oxidised tumour antigens to CD8+ T cells (2017) (7)
- Targeting early events in T cell activation to construct improved vaccines. (2000) (6)
- Nanoparticle System Based on Amino-Dextran as a Drug Delivery Vehicle: Immune-Stimulatory CpG-Oligonucleotide Loading and Delivery (2020) (6)
- Strains of Mycobacterium avium differentially activate human dendritic cells (2010) (4)
- Dry Formulation of Virus-Like Particles in Electrospun Nanofibers (2021) (4)
- The Influence of Microbial Metabolites in the Gastrointestinal Microenvironment on Anticancer Immunity (2019) (3)
- MIS416 as a siRNA Delivery System with the Ability to Target Antigen-Presenting Cells (2018) (3)
- Bridging Small Molecules to Modified Bacterial Microparticles Using a Disulphide Linkage: MIS416 as a Cargo Delivery System (2015) (2)
- Obesity Has a Systemic Effect on Immune Cells in Naïve and Cancer-Bearing Mice (2021) (2)
- Data on the uptake of CpG-loaded amino-dextran nanoparticles by antigen-presenting cells (2021) (1)
- Data on the uptake of reducible antigen-adjuvant conjugates by dendritic cells (2019) (1)
- Late-stage MC38 tumours recapitulate features of human colorectal cancer – implications for appropriate timepoint selection in preclinical studies (2023) (0)
- Additional file 1: Figure S1. of Multi-target chimaeric VLP as a therapeutic vaccine in a model of colorectal cancer (2017) (0)
- Calpains Released from Necrotic Tumor Cells Enhance Antigen Cross-Presentation to Activate CD8+ T Cells In Vitro (2022) (0)
- Abstract P4-06-20: Delivering tumour antigens survivin and mucin-1 on virus-like particles for breast cancer immunotherapy (2019) (0)
- Effect of carrier molecular weight on physicochemical properties and the in vitro immune-stimulatory activity of the CpG-dextran conjugates. (2022) (0)
- Abstract B186: Tumor cell-derived proteases contribute to antigen processing and enhance cross-presentation (2019) (0)
- A RANTES/hemagglutinin fusion DNA vaccine delivered by gene gun, induces a mixed Th1/Th2 response to influenza virus contrasting with a Th2 response to hemagglutinin alone (2005) (0)
- THE USE OF RHDV VIRUS-LIKE PARTICLES AS AN IMMUNOTHERAPY FOR HUMAN PAPILLOMAVIRUS TYPE 16 TUMOURS (2008) (0)
- Virus-like particle mediated delivery of a-galactosylceramide improves the generation of anti-tumour responses (2012) (0)
- Synthesis of Novel Glycolipid Mimetics of Heparan Sulfate and Their Application in Colorectal Cancer Treatment in a Mouse Model (2022) (0)
- Oncolytic virus-derived type I interferon restricts CAR T cell therapy (2020) (0)
This paper list is powered by the following services:
Other Resources About Sarah Young
What Schools Are Affiliated With Sarah Young ?
Sarah Young is affiliated with the following schools: